Negotiated and closed a 200M RMB pre-clinical companion diagnostics global licensing deal with a top Chinese research institute.Negotiated and closed a near 400M USD IND-staged protein degrader licensing and equity investment deal with a U.S. NASDAQ-listed biotech.Serving on the board of the U.S. diagnostics biotech that the company has invested in.

Negotiated and closed a >$100M licensing and equity investment deal of two I-O programs from a U.S. NASDAQ-listed biotech.

1. Negotiated and closed a 230 million RMB small molecule targeted therapy licensing-in from a Chinese biotechnology company;2. Negotiated and closed a bispecifics antibody licensing-in from a public European biotechnology company;3. Negotiated and closed a 50 million RMB biosimilar licensing-in from a Chinese biotechnology company;4. Worked in the negotiating team and closed a joint venture set-up with a U.S. biotechnology company;5. Managed the post-alliance collaborations with both domestic and foreign partners, including biologics manufacturing out-sourcing and quality control set-up, NDA filing and dossier preparation, and investment management;7. Evaluated more than 80 projects (small molecules, biologics, cell and gene therapies) from domestic and international biotechnology and pharmaceutical companies, covering areas such as oncology, diabetes and diagnostics;8. Managed the department's operation, including budget and HR management.

1. Negotiated and closed a US$4 million investment in a U.S. diagnostics company and a joint venture set-up in China;2. Managed the post-alliance collaboration with foreign partners, including JV's business plan drafting, financial and global clinical trial managements;3. Evaluated more than 40 projects from domestic and international biotechnology and pharmaceutical companies, covering areas such as oncology, diabetes and diagnostics;4. Managed the department's operation, including budget and HR management.

1. Negotiated and closed a technology collaboration agreement with an Israeli biotechnology company - Beta-O2 Technologies, Ltd.2. Negotiated and closed a US$5 million investment in an Israeli biotechnology company - Beta-O2 Technoglogies, Ltd. - and a joint venture set-up in China.

1. Develop an innovative chemical biology approach to identify and study the substrates of human protein arginine methyltransferases (PRMTs).2. Significantly expand the substrate database of PRMTs.3. Manage more than 5 collaboration projects concurrently.4. Mentor 7 junior students.

1. Develop multi-step small molecule synthesis to attack the human pathogen H. pylori.